|
Toward complement inhibition 2.0: Next generation anticomplement agents for paroxysmal nocturnal hemoglobinuria
|
Jan 2018
|
Am J Hematol
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Toward resolving the unsettled role of iron chelation therapy in myelodysplastic syndromes
|
Mar 2014
|
Expert Rev Anticancer Ther
|
myelodysplastic syndromes (MDS)
|
|
TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
|
Nov 2016
|
N Engl J Med
|
myelodysplastic syndromes (MDS)
|
|
TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases
|
May 2015
|
J Hematol Oncol
|
myelodysplastic syndromes (MDS)
|
|
TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups.
|
Jan 2019
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype
|
Jul 2020
|
Blood
|
acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
|
|
Traipsing Through Muddy Waters: A Critical Review of the Myelodysplastic Syndrome/Myeloproliferative Neoplasm (MDS/MPN) Overlap Syndromes
|
Apr 2021
|
Hematology/oncology clinics of North America
|
myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN)
|
|
Transfusion Thresholds, Quality of Life, and Current Approaches in Myelodysplastic Syndromes
|
Apr 2016
|
Anemia
|
myelodysplastic syndromes (MDS)
|
|
Transfusion-free interval is associated with improved survival in patients with higher-risk myelodysplastic syndromes engaged in routine care
|
Jun 2018
|
Leuk Lymphoma
|
myelodysplastic syndromes (MDS)
|
|
Translocation (8;21) acute myeloid leukemia presenting as severe aplastic anemia
|
Jun 2014
|
Leuk Res Rep
|
aplastic anemia
|
